Polyphosphokinase mutant with high catalytic activity and application thereof in synthesis of glutathione
By mutation of polyphosphate kinase at specific sites, a high catalytic activity mutant was designed, which solved the problem of low catalytic efficiency, achieved efficient ATP regeneration and glutathione synthesis, significantly improved production efficiency and reduced The cost.
Patent Information
- Application Number
- CN202411351917.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-26
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2044-09-26
AI Technical Summary
The catalytic efficiency of polyphosphate kinase is not high, limiting its efficiency in ATP regeneration system in industrial applications and the production efficiency of glutathione synthesis.
By performing specific site mutations on the amino acid sequence of polyphosphate kinase, such as mutations at positions 234 and 166, the highly catalytically active polyphosphate kinase mutants chPPK-N234A and chPPK-N234A/K166D, for use in the use of Build an efficient ATP regeneration system and glutathione synthesis reaction.
The enzyme activity of the mutant was increased by 4.19 times and 6.12 times, significantly accelerating the circulating regeneration of ATP and the synthesis rate of glutathione, and reducing production costs.
Smart Images

Figure CN118931871A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of bioengineering, and in particular to a polyphosphate kinase mutant with high catalytic activity and application thereof in synthesizing glutathione. Background Art
[0002] Glutathione (GSH) is a biologically active non-protein short thiol peptide, which is formed by the condensation of glutamic acid, glycine and cysteine. It has the functions of antioxidant, detoxifier and immune enhancement, and is widely used in medical, food and cosmetic industries. The enzyme-catalyzed synthesis of GSH has the advantages of simple components, high product concentration, short cycle and high yield, and has become a hot topic of research. However, two molecules of adenosine triphosphate (ATP) are consumed for each molecule of GSH synthesized. Therefore, the recycling of ATP in the synthesis system becomes a key factor in the efficiency of GSH biosynthesis.
[0003] The cleavage of ATP high-energy phosphate bonds provides the energy required for the enzymatic synthesis of GSH, but ATP is expensive. Direct addition significantly increases the cost of industrial production and also produces accumulation of byproducts such as adenine diphosphate or adenine monophosphate, making downstream separation and purification difficult. n ) provides a phosphate source and uses ADP or AMP as a substrate to synthesize ATP. Glutathione bifunctional enzyme (GshF) and PPK catalyze the synthesis of GSH, which can achieve efficient synthesis of GSH. At the same time, ADP / AMP can be used by polyphosphate to achieve the regeneration of ATP and the synthesis of GSH.
[0004] The ATP regeneration system based on polyphosphate kinase is efficient, stable and easy to scale up industrially. However, the catalytic efficiency of polyphosphate kinase in this ATP cycle system is not high, which limits its industrial application. Therefore, obtaining highly active polyphosphate kinase through molecular modification and constructing an efficient ATP regeneration system have important application value and research significance for large-scale enzymatic synthesis of GSH. Summary of the invention
[0005] The present invention is made to solve the above problems, and its object is to provide a polyphosphate kinase mutant with high catalytic activity.
[0006] In a first aspect, the present invention provides a polyphosphate kinase mutant with high catalytic activity, characterized in that: the polyphosphate kinase mutant is a polyphosphate kinase mutant in which the amino acid sequence shown in SEQ ID NO:2 is mutated to one of the following: (1) a single mutation at position 234 of the amino acid sequence shown in SEQ ID NO:2; (2) a double mutation at positions 234 and 166 of the amino acid sequence shown in SEQ ID NO:2.
[0007] Among them, the nucleotide sequence encoding the gene encoding the amino acid sequence shown in SEQ ID NO: 2 is as shown in SEQ ID NO: 1.
[0008] In some embodiments, the single mutation comprises mutating asparagine at position 234 to alanine, the amino acid sequence is shown in SEQ ID NO.4, and the nucleotide sequence is shown in SEQ ID NO.3.
[0009] In some embodiments, the double mutation includes mutating asparagine at position 234 to alanine, and mutating lysine at position 166 to aspartic acid, the amino acid sequence is shown in SEQ ID NO.6, and the nucleotide sequence is shown in SEQ ID NO.5.
[0010] The second aspect of the present invention provides a gene encoding the polyphosphate kinase mutant as described in the first aspect.
[0011] The third aspect of the present invention provides a recombinant vector comprising a gene encoding the polyphosphate kinase mutant as described in the second aspect.
[0012] The fourth aspect of the present invention provides a recombinant strain comprising a gene encoding the polyphosphate kinase mutant as described in the second aspect.
[0013] The fifth aspect of the present invention provides a method for preparing a polyphosphate kinase mutant, which has the following characteristics, comprising the following steps: (1) The coding gene shown in SEQ ID NO.1 was connected to the original expression vector pET-28a (+) to obtain the recombinant vector pET28a- Ch PPK, the recombinant vector pET28a- Ch PPK transformed host cells ch PPK recombinant strain; (2) Designing primers for site-directed mutagenesis of N234A, using the recombinant vector pET28a- Ch PPK was used as a template for overlap extension PCR to obtain the amino acid sequence shown in SEQ ID NO.4 in which the asparagine at position 234 was mutated to alanine. Ch PPK -N234A mutation vector; (3) Ch Transformation of PPK-N234A mutant vector into host bacteria E. coli BL21 (DE3) was screened and obtained Ch PPK-N234A polyphosphate kinase mutant expression strain, induced expression, obtained Ch PPK-N234A polyphosphate kinase mutant.
[0014] The sixth aspect of the present invention provides a method for preparing a polyphosphate kinase mutant, which has the following characteristics, comprising the following steps: (1) The coding gene shown in SEQ ID NO.1 was connected to the original expression vector pET-28a (+) to obtain the recombinant vector pET28a- Ch PPK, the recombinant vector pET28a- Ch PPK transformed host cells ch PPK recombinant strain; (2) Designing primers for site-directed mutagenesis of N234A, using the recombinant vector pET28a- Ch PPK was used as a template for overlap extension PCR to obtain the amino acid sequence shown in SEQ ID NO.4 in which the asparagine at position 234 was mutated to alanine. Ch PPK -N234A mutation vector; (3) Design K166D site-directed mutagenesis primers using the primers in step (2) Ch PPK-N234A mutant vector was used as a template for overlap extension PCR to obtain the amino acid sequence shown in SEQ ID NO.6, in which the 166th lysine was mutated to aspartic acid. Ch PPK-N234A / K166D mutation vector; (4) Ch PPK-N234A / K166D mutation vector was transformed into host bacteria E. coli BL21 (DE3) was screened and obtained Ch PPK-N234A / K166D polyphosphate kinase mutant expression strain, induced expression, obtained Ch PPK -N234A / K166D polyphosphate kinase mutant.
[0015] The seventh aspect of the present invention provides a use of the polyphosphate kinase mutant as described in the first aspect, characterized in that the polyphosphate kinase mutant is used to construct an ATP regeneration system.
[0016] The eighth aspect of the present invention provides an application of a polyphosphate kinase mutant, characterized in that the polyphosphate kinase mutant, a polyphosphate kinase mutant-expressing microorganism or a cell disrupted liquid thereof is used as an ATP regenerating agent for synthesizing glutathione.
[0017] By implementing the above technical solution, the present invention has the following beneficial effects: Single-site mutation polyphosphate kinase mutant provided by the present invention ch PPK-N234A and double-site mutation polyphosphate kinase mutants ch PPK-N234A / K166D has high activity, with the enzyme activity increased by 4.19 times and 6.12 times respectively compared with the wild-type polyphosphate kinase.
[0018] The invention provides an application of a polyphosphate kinase mutant, wherein the polyphosphate kinase mutant is used to construct an ATP regeneration system. The polyphosphate kinase mutant has high catalytic activity and can catalyze the byproduct ADP in the reaction process to synthesize ATP, thereby realizing the cyclic regeneration of ATP. Moreover, the ADP conversion rate of the polyphosphate kinase mutant is higher than that of the wild-type polyphosphate kinase mutant.
[0019] The present invention provides the use of polyphosphate kinase mutants in glutathione synthesis. Two polyphosphate kinase mutants are used as ATP regenerators to assist glutathione synthesis reaction, significantly accelerating the reaction rate. ch PPK-N234A can produce 17.86 g / L of glutathione within 4 h. ch PPK-N234A / K166D could produce 18.31 g / L of glutathione within 4 h. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 is the relative enzyme activity of the wild type polyphosphate kinase and its mutant in Example 4; Figure 2 is the curve of ADP conversion rate of polyphosphate kinase changing with time in Example 5; Figure 3 This is the curve of glutathione production changing over time when polyphosphate kinase is used for glutathione synthesis in Example 6. DETAILED DESCRIPTION
[0021] In order to make the technical means, creative features, objectives and effects achieved by the present invention easier to understand, the present invention is described in detail below in conjunction with embodiments and drawings.
[0022] The molecular biology experiments in the embodiments, including plasmid construction, enzyme digestion, ligation, competent cell preparation, transformation, culture medium preparation, etc., are mainly carried out with reference to Molecular Cloning Experiment Guide (3rd edition, edited by J. Sambrook and DW Russell (USA), translated by Huang Peitang et al., Science Press, Beijing, 2002).
[0023] LB medium: 10 g / L sodium chloride, 10 g / L peptone, 5 g / L yeast extract, 2 g / L agar powder (solid culture medium), solvent is water, pH natural.
[0024] Example 1: Site-directed mutagenesis of positions 234 and 166 of polyphosphate kinase 1. Site-directed mutagenesis In this study, we first used Alphafold 3 to ch PPK homology modeling was performed to predict its 3D structure. ch PPK and ADP molecular docking generation ch PPK_ADP.pdb file, and then visualize the docking results in Pymol and find the amino acid residues within 20 Å of ADP, and initially construct a large mutation library. In order to reduce the size of the library, the active site that directly interacts with ADP and the amino acid residues located on the key structures (lid structure, loop, Walker A and Walker B) were manually excluded. Although the mutation library was relatively small, it was still too large. Therefore, FoldX was further used to repair ch PPK_ADP.pdb file and virtual saturation mutation were used to narrow the amino acid residue sites in the mutant library. Some results are shown in Table 1. In theory, the higher the predicted free energy, the greater the flexibility of the enzyme structure, which is more likely to improve the catalytic activity of the enzyme. Based on this, high-energy sites with significantly improved free energy of the mutants were selected for further experimental verification. Through this strategy, a smaller mutant library with experimental feasibility was finally obtained, and the beneficial mutation sites N234 and K166 were obtained.
[0025] To mutate positions 234 and 166 of wild-type polyphosphate kinase to predicted amino acids, ch The coding gene sequence of PPK was used as a template, the amino acid sequence of which is shown in SEQ ID NO.2, and the nucleotide sequence of which is shown in SEQ ID NO.1. The corresponding primers were designed and the pET28a- Ch PPK was used for whole plasmid amplification, and the primer sequences are shown in Table 2.
[0026] The PCR amplification system was (50 µL): 1 µL template DNA, 25 µL 2×Phanta Max Buffer, 1 µL dNTPsMix, 1 µL each of upstream and downstream primers, 1 µL Phanta DNA Polymerase, and ddH2O to a total volume of 50 µL.
[0027] PCR reaction parameters: (1) 95 °C pre-denaturation for 30 s; (2) 95 °C denaturation for 30 s; (3) 55 °C annealing for 30 s; (4) 72 °C extension for 6 min, steps (2)-(4) cycle 30 times; (5) 72 °C full extension for 7 min, stored at 16 °C. After the PCR product was positive after 0.9% agarose gel electrophoresis analysis, 1 μL of endonuclease Dpn I was added to the PCR reaction solution and digested at 37 °C for 2 h to remove the template plasmid DNA.
[0028] Table 1 Virtual saturation mutation energy table based on FoldX (partial) Amino acid N234 K166 E152 S101 A 1.287 0.307 1.246 -0.403 C 1.863 0.836 0.793 -0.816 D 1.917 -0.032 0.531 -0.598 E 1.563 -0.391 0.000 -1.167 F 1.118 0.305 -1.372 -0.178 G 2.114 0.913 1.783 0.046 H 1.925 0.761 0.202 -1.277 I 1.203 0.534 -0.758 -2.309 K 1.106 0.000 0.718 -1.111 L 1.183 0.211 -0.534 -1.969 M 0.658 -0.060 -0.095 -1.475 N 0.000 0.218 1.139 -0.709 P 5.804 -0.892 1.406 -0.419 Q 1.014 -0.048 -0.003 -0.818 R 1.032 0.053 0.774 -0.460 S 1.282 0.538 2.103 0.000 T 1.062 0.731 1.545 -1.103 V 1.548 0.761 -0.290 -1.645 W 1.424 0.391 -0.878 -0.915 Y 1.382 0.447 -1.302 -0.280 Table 2 Primers for site-directed mutagenesis of polyphosphokinase at position 234 and position 166 2. Transformation and culture of polyphosphate kinase mutants Take 10 μL of the PCR product from step 1 and add E. coli BL21 (DE3) competent cells were placed on ice for 30 min, heat-shocked at 42 °C for 90 s, and 600 μL of LB liquid medium without antibiotics was added. The cells were cultured at 37 °C at 180 r / min for 1 h, and then spread on LB plates containing 50 μg / mL kanamycin and cultured at 37 °C overnight. Single colonies on the plates were randomly picked and transferred to 10 mL LB liquid medium containing 50 μg / mL kanamycin. After culturing at 37 °C for 8 h, 500 μL of bacterial solution and 30% glycerol (v / v=1:1) were mixed in a glycerol tube and stored in a -80 °C refrigerator. The remaining bacterial solution was sent to Beijing Qingke Biotechnology Co., Ltd. for sequencing, and 10 polyphosphate kinase mutant recombinant engineered bacteria were finally obtained.
[0029] Example 2: Construction of a polyphosphate kinase iterative mutation library The best single mutant in Example 1 ch PPK-N234A was iteratively mutated to ch The coding gene sequence of PPK-N234A was used as a template, and the primers designed in Example 1 were used to clone pET28a- ChPPK-N234A was fully amplified. The operations of full plasmid amplification, mutant transformation and culture were as shown in Example 1, and finally a polyphosphate kinase double-site mutant was obtained. ch PPK-N234A / K166H and ch PPK-N234A / K166D.
[0030] Example 3: Preparation of cell lysate of recombinant Escherichia coli containing polyphosphate kinase mutant The recombinant engineered bacteria involved in Example 1 were inoculated into 10 mL LB medium containing 50 μg / mL kanamycin and cultured at 37°C and 180 rpm for 8 h as seed solution. The seed solution was then inoculated into 50 mL LB liquid medium containing 50 μg / mL kanamycin at a 2% (v / v) inoculation rate and cultured at 37°C and 180 rpm for 2-3 h to obtain a bacterial cell concentration of OD 600 When the pH value reaches 0.5-0.7, add isopropyl-β-D-thiogalactopyranoside (IPTG) to the culture medium at a final concentration of 0.1 mM, and induce the culture at 28 °C and 180 rpm for 12 h. The harvested cells are centrifuged at 4 °C and 8000 rpm for 10 min, and the wet cells are collected for later use.
[0031] The collected bacteria were resuspended at 1 g / L in 50 mM Tris-HCl buffer (pH=7.5) and disrupted by ultrasound, with each working cycle lasting 1 s and a rest period of 2 s for a total working time of 10 min. The resulting cell disruption solution was diluted 10 times to a final concentration of 0.1 g / L.
[0032] Example 4: Determination of polyphosphate kinase activity The cell lysate of the recombinant Escherichia coli containing the wild-type polyphosphate kinase and the polyphosphate kinase mutant obtained in Example 3 was subjected to enzyme activity assay.
[0033] 50 µL of 25 mM ADP, 50 mM sodium hexametaphosphate, and 100 mM anhydrous magnesium sulfate prepared in 50 mM Tris-HCl buffer (pH=7.5) were added to 100 µL of 0.1 g / L cell disruption solution, respectively. After reacting at 35 °C and 600 rpm for 5 min, 50 µL of 2 M HCl was added to terminate the reaction, and 50 µL of 2 M NaOH was added to neutralize the pH. The reaction solution was centrifuged at 1000 r / min for 1 min, the supernatant was diluted 2 times with ultrapure water, and then filtered through a 0.22 µm water filter membrane, and the ATP content was detected by high performance liquid chromatography (HPLC).
[0034] Enzyme activity definition: The amount of enzyme required to generate 1 µmol ATP per minute at 35°C and pH 7.5 is defined as one enzyme activity unit (U).
[0035] The conditions for HPLC detection of ATP content were as follows: C18 column (4.6×mmol / L, 5 µm), 50 mM potassium dihydrogen phosphate as mobile phase (pH = 7.0 adjusted with potassium dihydrogen phosphate, prepared immediately before use), 10 µL injection volume, 0.8 mL / min flow rate, 40 °C, 8 min retention time, 254 nm detection, ATP, ADP, and AMP eluted in sequence.
[0036] The results of enzyme activity assay are shown in Figure 1 , single site mutation polyphosphate kinase mutant ch PPK-N234A and double-site mutation polyphosphate kinase mutants ch The enzyme activity of PPK-N234A / K166D was significantly improved, which was 4.19 times and 6.12 times higher than that of wild-type polyphosphate kinase, respectively.
[0037] Example 5: Wild-type polyphosphate kinase ch Application of PPK and its mutants in catalyzing ATP synthesis Prepared according to Example 3 ch PPK, ch PPK-N234A, ch PPK-N234A / K166D cell lysis solution, 5 mL of 25 mM ADP, 50 mM sodium hexametaphosphate, and 100 mM anhydrous magnesium sulfate prepared with 50 mM Tris-HCl buffer (pH=7.5) were added to 10 mL of 0.1 g / L cell lysis solution, and the mixture was shaken in a water bath at 35 °C and 600 rpm. 250 μL of the sample was taken at different time points, and 50 μL of 2 M HCl and NaOH were added in sequence. The sample treatment method and HPLC detection method are shown in Example 4.
[0038] The reaction process of polyphosphate kinase changes with time. Figure 2 As shown, wild-type polyphosphate kinase ch The conversion rate of PPK tended to be stable at 125 min, and the final conversion rate was about 63%. ch PPK-N234A and ch The conversion rates of PPK-N234A / K166D were about 39% and 57% at 2 min, respectively, while the conversion rate of the wild type was only about 3%. The conversion rates of both mutants tended to stabilize at 100 min, and the final conversion rate was about 68%.
[0039] Example 6: Application of polyphosphate kinase in glutathione synthesis The composition and operation of the reaction system were as follows: 60 mM cysteine, 90 mM glutamate sodium salt, 100 mM glycine, 60 mM anhydrous magnesium sulfate, 35 mM sodium hexametaphosphate and 12.5 g / L and 5 g / L wet bacterial volume of glutathione bifunctional enzyme (GshF) cell disruption solution and polyphosphate kinase cell disruption solution were added to 100 mM Tris-HCl buffer (pH=7.5), and then 2 mM ATP was added. The reaction was shaken at 35 °C and 600 rpm for 4 h. During this period, nitrogen was continuously introduced and the pH was adjusted to 7.0.
[0040] Take 1 mL from the reaction system intermittently, add 100 µL 2 M HCl to terminate the reaction, and then add NaOH of the same volume concentration. Centrifuge at 12000 r / min for 1 min, take the supernatant and dilute it 10 times with pure water, filter it through a 0.22 µm water filter, and detect the glutathione (GSH) content by HPLC.
[0041] HPLC detection conditions: C18 chromatographic column (4.6×mmoL / L, 5 µm), prepare a solution of potassium dihydrogen phosphate and sodium heptane sulfonate with final concentrations of 6.8 g / L and 2.02 g / L, respectively, adjust the pH to 2.8 with phosphoric acid, take 950 mL of the mixed solution and add 50 mL of pure methanol to obtain the mobile phase, 10 µL injection volume, 1.0 mL / min, column temperature 30 °C, retention time 20 min, detection at 210 nm.
[0042] Wild-type polyphosphate kinase ch PPK and its mutants ch PPK-N234A, ch The reaction process of PPK-N234A / K166D for glutathione synthesis changes with time. Figure 3 Wild type ch After PPK was used for glutathione synthesis reaction for 4 hours, the glutathione content was 16.31 g / L. ch After 4 h of reaction, the glutathione production of PPK-N234A increased to 17.86 g / L. ch After 4 h of reaction, the glutathione production of PPK-N234A / K166D was 18.31 g / L.
[0043] Embodiment 7: ch Comparison examples between different PPK mutants In previous work (application number: CN202310871912.5), we chSingle-point saturation mutations were performed at positions 56 and 125 of the PPK amino acid sequence, and two polyphosphate kinase mutants with significantly improved activity were successfully constructed: ch PPK-E56K and ch PPK-T125S. ch The enzyme activity of PPK-E56K was increased by 4.8 times compared with the wild type. ch The enzyme activity of PPK-T125S reached 5.3 times that of the wild type.
[0044] In this study, we further constructed ch The PPK-N234A / K166D double mutant further improved the enzyme activity. Under the same reaction conditions, the enzyme activity of the double mutant increased by 6.12 times compared with the wild type, showing excellent catalytic efficiency.
[0045] also, ch PPK-E56K and ch The application of PPK-T125S as an ATP regenerator in glutathione synthesis shows that when the enzyme dosage is 25 g / L, the constructed ATP regeneration system can support the effective glutathione synthesis reaction. ch PPK-N234A / K166D can reduce the amount of PPK enzyme to 5 g / L, which is 20% of the previous dosage.
[0046] In summary, ch The PPK-N234A / K166D double mutant not only has the highest relative enzyme activity compared to the wild type, but can also significantly accelerate the rate of ATP generation and improve reaction efficiency. In practical applications, when coupled with glutathione bifunctional enzyme (GshF) to catalyze the synthesis of glutathione, it further reduces the amount of enzyme input in the reaction, effectively reducing production costs.
[0047] The above-mentioned embodiments are preferred examples of the present invention and are not intended to limit the protection scope of the present invention.
Claims
1. A polyphosphate kinase mutant with high catalytic activity, Features: The polyphosphate kinase mutant is a polyphosphate kinase mutant in which the amino acid sequence shown in SEQ ID NO: 2 is mutated into one of the following: (1) a single mutation is made at position 234 of the amino acid sequence shown in SEQ ID NO: 2; (2) a double mutation is made at positions 234 and 166 of the amino acid sequence shown in SEQ ID NO:
2.
2. The polyphosphate kinase mutant according to claim 1, Features: The single mutation includes mutating asparagine at position 234 to alanine, the amino acid sequence is shown in SEQ ID NO.4, and the nucleotide sequence is shown in SEQ ID NO.
3.
3. The polyphosphate kinase mutant according to claim 1, Features: The double mutation includes mutating asparagine at position 234 to alanine and mutating lysine at position 166 to aspartic acid. The amino acid sequence is shown in SEQ ID NO.6, and the nucleotide sequence is shown in SEQ ID NO.
5.
4. A gene encoding the polyphosphate kinase mutant according to any one of claims 1 to 3.
5. A recombinant vector comprising the coding gene according to claim 4. A recombinant strain comprising the coding gene according to claim 4.
7. A method for preparing the polyphosphate kinase mutant according to claim 2, It is characterized in that The following steps are involved: The coding gene shown in SEQ ID NO.1 was connected with the original expression vector pET-28a (+) to obtain the recombinant vector pET28a- Ch PPK, the recombinant vector pET28a- Ch PPK transformed host cells ch PPK recombinant strain; Design the N234A site-directed mutagenesis primers and use the recombinant vector pET28a- Ch PPK was used as a template for overlap extension PCR to obtain the amino acid sequence shown in SEQ ID NO.4 in which the asparagine at position 234 was mutated to alanine. Ch PPK -N234A mutation vector; Will Ch Transformation of PPK-N234A mutant vector into host bacteria E. coli BL21 (DE3) was screened and obtained Ch PPK-N234A polyphosphate kinase mutant expression strain, induced expression, obtained Ch PPK-N234A polyphosphate kinase mutant.
8. A method for preparing the polyphosphate kinase mutant according to claim 2, It is characterized in that The following steps are involved: The coding gene shown in SEQ ID NO.1 was connected with the original expression vector pET-28a (+) to obtain the recombinant vector pET28a- Ch PPK, the recombinant vector pET28a- Ch PPK transformed host cells ch PPK recombinant strain; Design the N234A site-directed mutagenesis primers and use the recombinant vector pET28a- Ch PPK was used as a template for overlap extension PCR to obtain the amino acid sequence shown in SEQ ID NO.4 in which the asparagine at position 234 was mutated to alanine. Ch PPK -N234A mutation vector; Design K166D site-directed mutagenesis primers using the primers in step (2) Ch PPK-N234A mutant vector was used as a template for overlap extension PCR to obtain the amino acid sequence shown in SEQ ID NO.6 in which the 166th lysine was mutated to aspartic acid. Ch PPK -N234A / K166D mutation vector; Will Ch PPK-N234A / K166D mutation vector was transformed into host bacteria E. coli BL21 (DE3) was screened and obtained Ch PPK-N234A / K166D polyphosphate kinase mutant expression strain, induced expression, obtained Ch PPK -N234A / K166D polyphosphate kinase mutant.
9. A use of the polyphosphate kinase mutant as claimed in claim 2, Features: The polyphosphate kinase mutant is used to construct an ATP regeneration system.
10. A use of the polyphosphate kinase mutant as claimed in claim 2, Features: The polyphosphate kinase mutant, the polyphosphate kinase mutant-expressing microorganism or the cell disrupted liquid thereof is used as an ATP regenerating agent for synthesizing glutathione.
Citation Information
Patent Citations
Polyphosphokinase mutant, coding gene, recombinant vector, recombinant strain, preparation method and application thereof
CN117025565A
Polyphosphate kinase mutant and application thereof in glutamine synthesis
CN115806957A
PRPP synthetase mutant and application thereof in efficient synthesis of NAD and NADP coenzyme
CN117417915A
Cited By
Polyphosphokinase mutant, recombinant genetically engineered bacterium for expressing mutant and application of recombinant genetically engineered bacterium
CN119162147A
Polyphosphokinase mutant with improved thermal stability and application
CN119776317A
